bladder cancer
Conditions
Interventions
Experimental group:Organoid susceptibility testing guides neoadjuvant chemotherapy drug selection
Sponsors
The Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Patients with pathologically diagnosed bladder myometrial invasive bladder cancer cT2-4; (2) male or female aged 18-85 years; (3) ECOG PS status score of 0-1; (4) The screening laboratory value must meet the following standards: WBC >2.0*10^9/L, neutrophil > 1.0*10^9/L, platelet > 100*10^9/L, hemoglobin >90 g/L; AST <2.5 * ULN, ALT < 2.5 * ULN, bilirubin < 1.5 * ULN; (ULN: Upper limit of normal); ?GFR=50ml/min (6) Ability to follow research and follow-up procedures; (7) The patient has the ability to understand and voluntarily sign informed consent;
Exclusion criteria
Exclusion criteria: (1) Receive a live attenuated vaccine within 4 weeks prior to enrollment or during the study period; (2) Female patients planning pregnancy or breastfeeding; (3) Hearing loss> grade 2; (4) Heart failure NYHA grade > III.; (5) Peripheral neuropathy> grade 2; (6) Severe infection within 2 weeks prior to participation in the study, including but not limited to hospitalization due to complications of infection, bacteremia or severe pneumonia; (7) Previous or concurrent malignant tumors whose natural history or treatment may interfere; (8) the presence of severe or uncontrollable systemic disease;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate; | — |
Countries
China
Contacts
Public ContactZhangChangWen
The Second Hospital of Tianjin Medical University
Outcome results
None listed